MODEL VERDICT
Ultragenyx Pharmaceutical Inc. (RARE) — Relative Valuation
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| Feb 28, 2026 | MODERATE | 0.62 | $23.39 | CURRENT | — |
| Feb 21, 2026 | MODERATE | 0.62 | $22.72 | CURRENT | — |
| Feb 14, 2026 | MODERATE | 0.62 | $20.52 | CURRENT | — |
| Feb 11, 2026 | MODERATE | 0.62 | $24.20 | CURRENT | — |
| Jan 11, 2026 | MODERATE | 0.65 | $22.51 | Pending | +6.1% |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| EV To Revenue 130 industry peers | $68.53 | +193.0% | 4% | B | Data |
| Price / Sales 130 industry peers | $71.02 | +203.6% | 3% | B | Model Driven |
| Weighted Output Blended model output | $83.13 | +255.4% | 100% | 58 | SIGNIFICANTLY UNDERVALUED |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 28.38 | 8.60 | 4.97 | 96.24 | 34.73 |
| P/B Ratio | 8.17 | 7.30 | 3.55 | 14.52 | 4.25 |
| P/S Ratio | 19.49 | 16.22 | 6.80 | 42.03 | 13.35 |
Based on our peer multiples analysis with 3 valuation metrics, the model estimates RARE's fair value at $83.13 vs the current price of $23.39, implying +255.4% upside potential. Model verdict: Significantly Undervalued. Confidence: 58/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $83.13 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%). Monte Carlo simulation (10,000 iterations) gives a range of $47.88 (P10) to $117.38 (P90), with a median of $81.90.
RARE's current P/E of -3.7x compares to the industry median of 21.4x (48 peers in the group). This represents a -117.4% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
33 analysts cover RARE with a consensus rating of Buy. The consensus price target is $48.78 (range: $34.00 — $63.00), implying +108.6% upside from the current price. Grade breakdown: Strong Buy (0), Buy (27), Hold (5), Sell (1), Strong Sell (0).
The model confidence score is 58/100, based on: data completeness (6), peer quality (25), historical depth (20), earnings stability (5), and model agreement (2). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for RARE.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.